Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christina Arakaki

Optometrist Fullerton, CA Doctor of Optometry

NPI 1396238671 CMS profile 4899164

101 Laguna Rd Ste C, Fullerton, CA 92835

Open in the dashboard

General payments

$10,103

272 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christina Arakaki of Fullerton, CA is reported in the CMS Open Payments database as having received $10,103 across 272 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $829 29
2024 General $1,185 28
2023 General $1,195 41
2022 General $1,530 57
2021 General $1,466 49
2020 General $636 18
2019 General $3,260 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christina Arakaki
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Christina Arakaki were reported at $829. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Christina Arakaki Optometrist median Middle half National median
2019 $3,260 $159 $67–$371 $163
2020 $636 $72 $29–$165 $114
2021 $1,466 $125 $46–$292 $132
2022 $1,530 $162 $66–$374 $149
2023 $1,195 $177 $72–$406 $160
2024 $1,185 $188 $77–$427 $164
2025 $829 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb, a division of Bausch Health US, LLC $2,861 30 payments
  2. Alcon Vision LLC $942 31 payments
  3. Allergan Inc. $859 19 payments
  4. Sun Pharmaceutical Industries Inc. $790 41 payments
  5. Dompe US, Inc. $653 19 payments
  6. Aerie Pharmaceuticals, Inc. $630 30 payments
  7. Glaukos Corporation $456 12 payments
  8. AbbVie, Inc. $309 11 payments
  9. Bausch & Lomb Americas Inc. $256 7 payments
  10. Oyster Point Pharma, Inc. $254 11 payments
  11. Other $2,093 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,295 263 payments
  2. Travel and Lodging $1,808 9 payments
Products named General payments · program years 2019–2025
  1. ULTRA $2,121 14 payments
  2. BIOTRUE $1,949 11 payments
  3. Cequa $790 41 payments
  4. OXERVATE $653 19 payments
  5. rhopressa Glaucoma $421 21 payments
  6. rocklatan $421 21 payments
  7. BIOTRUE ONE DAY $313 5 payments
  8. RESTASIS MULTIDOSE $304 9 payments
  9. INFUSE $279 4 payments
  10. Rhopressa Glaucoma $271 12 payments
  11. Other $7,047 223 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

272 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record